HMGB1 Carried by Small Extracellular Vesicles Potentially Plays a Role in Promoting Acquired Middle Ear Cholesteatoma
Authors:
- Michał W. ŁuczakMŁMichał W. Łuczak
- Karolina DżamanKarolina Dżaman
- Łukasz ZarębaŁZŁukasz Zaręba
- Katarzyna CzerwatyKCKatarzyna Czerwaty
- Jacek SiewieraJSJacek Siewiera
- Alicja GłuszkoAGAlicja Głuszko
- Ewa OlszewskaEOEwa Olszewska
- Jacek BrzostJBJacek Brzost
- Ireneusz KantorIKIreneusz Kantor
- Mirosław J. SzczepańskiMirosław J. Szczepański
- Nils LudwigNils Ludwig
Open Access
- 17 November 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3469
Abstract
Cholesteatoma is a specific medical condition involving the abnormal, non-cancerous growth of skin-like tissue in the middle ear, potentially leading to a collection of debris and even infections. The receptor for advanced glycation (RAGE) and its ligand, high-mobility box 1 (HMGB1), are both known to be overexpressed in cholesteatoma and play a potential role in the pathogenesis of the disease. In this study, we investigated the role of small extracellular vesicles (sEVs) in carrying HMGB1 and inducing disease-promoting effects in cholesteatoma. No significant differences in the concentration of isolated sEVs in the plasma of cholesteatoma patients (n = 17) and controls (n = 22) were found (p > 0.05); however, cholesteatoma-derived sEVs carried significantly higher levels of HMGB1 (p < 0.05). In comparison to sEVs isolated from the plasma of controls, cholesteatoma-derived sEVs significantly enhanced keratinocyte proliferation and IL-6 production (p < 0.05), potentially by engaging multiple activation pathways including MAPKp44/p42, STAT3, and the NF-κB pathway. Thus, HMGB1(+) sEVs emerge as a novel factor potentially promoting cholesteatoma progression.Keywords
Funding Information
- Centre of Postgraduate Medical Education (501-1-019-56-23, UMO-2017/25/B/NZ5/02949)
- National Science Centre, Poland (501-1-019-56-23, UMO-2017/25/B/NZ5/02949)
This publication has 48 references indexed in Scilit:
- Expression of the Receptor for Advanced Glycation End Products, a Target for High Mobility Group Box 1 Protein, and its Role in Chronic Recalcitrant Rhinosinusitis with Nasal PolypsArchivum Immunologiae et Therapiae Experimentalis, 2014
- Induction of cytokine production in cholesteatoma keratinocytes by extracellular high-mobility group box chromosomal protein 1 combined with DNA released by apoptotic cholesteatoma keratinocytesMolecular and Cellular Biochemistry, 2014
- Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesisJournal of Molecular Medicine, 2014
- Supporting cells regulate the remodelling of aminoglycoside‐injured organ of Corti, through the release of high mobility group box 1European Journal of Neuroscience, 2013
- PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesionsOral Oncology, 2013
- Deficiency in the Nuclear Factor E2-related Factor-2 Transcription Factor Results in Impaired Adipogenesis and Protects against Diet-induced ObesityJournal of Biological Chemistry, 2010
- Animal Model for Cholesteatoma Induced in the Gerbil: Will the Profiles of Differentiation/Growth-Regulatory Markers be Similar to the Clinical Situation?The Laryngoscope, 2007
- Reversing established sepsis with antagonists of endogenous high-mobility group box 1Proceedings of the National Academy of Sciences, 2003
- The Roles of Interleukin-1.ALPHA., Tumor Necrosis Factor-.ALPHA. and Parathyroid Hormone-Related Protein in Bone Resorption of Cholesteatoma Otitis.Nippon Jibiinkoka Gakkai Kaiho, 1994
- Bone-resorbing cytokines enhance release of macrophage colony-stimulating activity by the osteoblastic cell MC3T3-E1Calcified Tissue International, 1989